// App-Quantinova.ai

P1-13-02 : Early change in topoisomerase 1 (Top1) positive circulating tumor cells (CTCs) is associated with overall survival (OS) in patients with advanced breast cancer after treatment with etirinotecan pegol

Researchers

Presenter

  • Rugo HS

Principal Investigators

  • Cortes J

  • Awada A

  • Davis DW

  • Hoch U

  • Perez EA

  • Shaughnessy J

  • Twelves C

  • Im S-A

  • Hannah AL

  • Caygill K

  • Zajchowski D

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX

  • Seoul National University College of Medicine, Seoul, Korea

  • University of Leeds, Leeds, United Kingdom

  • Oncology Consulting Services, San Francisco, CA

  • Consultant, Sebastopol, CA

  • University of California, San Francisco, San Francisco, CA

Locations

  • Spain

  • United Kingdom

  • United States

  • Belgium

Companies

  • Nektar Therapeutics

  • Apocell, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • ATP-binding cassette super-family G member 2

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Cluster of differentiation 45

  • Proliferation marker protein Ki-67

  • Histone H2AX

Drug/Treatment

  • etirinotecan pegol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved